<DOC>
	<DOCNO>NCT01967784</DOCNO>
	<brief_summary>The aim study describe immunogenicity safety new formulation Quadrivalent Influenza Vaccine ( QIV ) 2013-2014 season Northern Hemisphere ( NH ) subject age 9 17 year Taiwan Primary Objective : - To describe immunogenicity QIV ( split-virion , inactivate ) NH seasonal formulation Secondary Objective : - To describe safety QIV ( split-virion , inactivate ) NH seasonal formulation</brief_summary>
	<brief_title>Study Quadrivalent Influenza Vaccine Administered Via Intramuscular Route Children Adolescents Taiwan</brief_title>
	<detailed_description>Study participant vaccinate one dose QIV ( split-virion , inactivate ) NH 2013-2014 formulation intramuscular route deep subcutaneous . Immunogenicity assess baseline ( Day 0 ) 21 day injection ; also followed-up safety 21 day injection .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 9 17 year day inclusion Assent form ( AF ) and/or inform consent form ( ICF ) sign date subject accord site requirement , ICF sign date parent ( ) another legally acceptable representative ( ) independent witness applicable Subject parent/legally acceptable representative able attend schedule visit comply trial procedure . Subject pregnant ( positive urine pregnancy test ) , lactate , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) Participation time study enrollment 4 week precede trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 3 week follow trial vaccination Vaccination influenza previous 12 month administer context clinical trial previous 6 month administer context flu vaccination campaign Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Selfreported history seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C , question Known systemic hypersensitivity egg , chicken protein , neomycin , formaldehyde octoxynol9 , vaccine component , history lifethreatening reaction vaccine use study vaccine contain substance Known suspect thrombocytopenia , contraindicate intramuscular vaccination base investigator 's judgment Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination upon investigator 's judgment Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥38.0°C ) . A prospective subject include study condition resolve febrile event subside Identified family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Quadrivalent Inactivated Influenza Vaccine</keyword>
</DOC>